ALK and anaplastic large cell lymphoma: To evaluate whether DNA-based minimal disease measurement might provide additional information beyond the standard RNA-based method, we compared RNA- and DNA-based quantification of NPM-ALK fusion sequences in two ALK+ ALCL cell lines (Karpas 299 and SR-786) incubated with different concentrations of the ALK kinase inhibitor crizotinib for 72 hours (Figure 5).